Full history for every metric is available with a Kvantra account
FibroGen, Inc. (FGEN)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 176 | 235 | 141 | 47 | 30 | 6 | 5 |
| Operating profit | $m | -46 | -50 | |||||
| Net profit | $m | -189 | -290 | -294 | -284 | -48 | 183 | 183 |
| EPS reported | $ | 45.37 | 45.30 | |||||
| Operating cashflow per share | $ | -1.18 | -9.40 | |||||
| Capex per share | $ | 0.01 | 0.00 | |||||
| FCF per share | $ | -1.19 | -9.40 | |||||
| Free cash flow | $m | -5 | -38 | |||||
| Net debt | $m | -89 | -91 | |||||
| Book value equity | $m | 4 | -8 | |||||
| Book value per share | $ | 1.11 | -2.01 | |||||
| Number of shares | m | 4.04 | 4.05 | |||||
| DPS (TTM paid) | $ | 0.98 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | 0.19 | - | |||||
| P/B LTM | x | 7.93 | -4.51 | |||||
| P/S LTM | x | 5.51 | 7.95 | |||||
| P/FCF LTM | x | -7.38 | -0.96 | |||||
| EV/EBITDA LTM | x | 0.27 | 1.45 | |||||
| EV/Sales LTM | x | -1.92 | -11.83 | |||||
| Earnings Yield LTM | % | 526.32% | 498.95% | |||||
| FCF Yield | % | -13.56% | -103.73% | |||||
| Quality | ||||||||
| ROE | % | 4099.5% | -2443.6% | |||||
| ROIC | % | -50.72% | -77.36% | |||||
| Operating margin | % | -712.66% | -1090.0% | |||||
| Gross margin | % | 0.00% | 78.44% | |||||
| FCF/Sales | % | -74.72% | -824.57% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -78.26% | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 11.12% | 0.00% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | 2.15% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 1.04 | 1.34 | |||||
| EBIT/Net interest | x | 5.24 | 82.62 | |||||
| Net debt/market cap | % | -250.66% | -248.88% | |||||
| Net debt/Equity | x | -19.88 | 11.21 | |||||
| Gross debt/equity | x | 0.00 | -0.00 | |||||
Company overview
FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes. Additionally, the company is progressing Pamrevlumab, a human monoclonal antibody designed to block connective tissue growth factor. Pamrevlumab is undergoing Phase III clinical development for multiple conditions including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, with a separate Phase III trial also underway for Duchenne muscular dystrophy. FibroGen maintains strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Established in 1993, FibroGen, Inc. operates from its headquarters in San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
FibroGen, Inc. (FGEN)
FibroGen, Inc. is a biopharmaceutical firm dedicated to discovering, developing, and bringing to market therapies that address significant medical conditions currently lacking effective treatments. Among its pipeline, FibroGen is advancing Roxadustat, an orally administered small molecule that inhibits hypoxia inducible factor prolyl hydroxylases. This drug has successfully completed Phase III clinical trials in the US, Europe, China, and Japan for treating anemia in chronic kidney disease, and is currently in Phase II/III development in China for anemia linked to myelodysplastic syndromes. Additionally, the company is progressing Pamrevlumab, a human monoclonal antibody designed to block connective tissue growth factor. Pamrevlumab is undergoing Phase III clinical development for multiple conditions including idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, with a separate Phase III trial also underway for Duchenne muscular dystrophy. FibroGen maintains strategic collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. Established in 1993, FibroGen, Inc. operates from its headquarters in San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free